Initial Form 3 filing shows Dr. Daniel Tardiff, Chief Scientific Officer and director at Camp4 Therapeutics (CAMP), reporting ownership entirely through stock options. He holds options covering 74,578 shares of common stock with exercise prices of $9.08, $3.86, and $3.53. Vesting schedules start on 09/18/2023 and 04/01/2025
FMR LLC and Abigail P. Johnson reported owning a combined 3,023,434 shares of Camp4 Therapeutics Corp common stock, representing 15.0% of the outstanding class as of 09/30/2025. FMR LLC identifies itself as the filing person and notes that Select Biotechnology Portfolio held 1,463,592 shares, or 7.3%, of the company at that date. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures show the form was executed on 10/06/2025 by an authorized representative.
Camp4 Therapeutics Schedule 13G/A: HarbourVest-affiliated entities report beneficial ownership of 1,271,948 shares of Camp4 common stock, representing 2.7% of the class. The shares are owned directly by SMRS-TOPE LLC, which holds sole voting and dispositive power over all 1,271,948 shares. HarbourVest Partners, LLC, HarbourVest Partners L.P. and HVST-TOPE LLC may be deemed to have shared voting and dispositive power but disclaim beneficial ownership. The filing includes a joint filing agreement among the reporting persons and is based on 46,842,126 shares outstanding used to calculate the 2.7% stake.
CAMP4 Therapeutics Corporation furnished an update that it has initiated GLP (good laboratory practice) toxicology studies for its program called CMP-SYNGAP-01. These studies are a standard non‑clinical step used to evaluate safety before a potential move into later development stages.
The update was shared through a press release titled “CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01,” which is included as an exhibit to this report. The information is being provided for disclosure purposes and is not being treated as filed under the securities laws unless specifically incorporated by reference elsewhere.
Vivo Opportunity funds disclosed ownership positions in Camp4 Therapeutics (CAMP). Together, Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,561,793 shares, representing 7.6% of the class based on a 46,878,487-share base that includes a 26,717,414-share private placement closed September 11, 2025. Separate Cayman entities, Vivo Opportunity Cayman Fund, L.P. and its GP, report beneficial ownership of 359,775 shares (0.8%). All reported shares are held of record by the named funds, and the filers state sole voting and dispositive power over the shares. The filing is a Schedule 13G indicating passive investment intent.
Coastlands-affiliated entities and Matthew D. Perry reported holding an aggregate of 4,886,722 shares of Camp4 Therapeutics Corp common stock. The filing lists that amount as representing 10.0% of the class on the cover sheets and as 9.99% in Item 4, reflecting the reporting persons' calculation based on 20,161,073 shares outstanding as of August 5, 2025 and an additional 26,681,053 shares issued in a private placement that closed September 11, 2025. Each reporting person disclaims beneficial ownership except to the extent of pecuniary interest and states the shares are held in the ordinary course of business and not to influence control of the issuer. All reporting persons show shared voting and dispositive power over the 4,886,722 shares and no sole voting or dispositive power.
Andrew J. Schwab, a director and 10% owner of Camp4 Therapeutics Corp (CAMP), reported an acquisition on Form 4. The filing shows a transaction dated 09/11/2025 in which 2,941,176 shares of common stock were acquired at $1.53 per share. The shares are reported as indirectly owned through 5AM Ventures VII, L.P. The filing also discloses additional indirect holdings attributed to related 5AM entities: 2,625,145 shares held by 5AM Ventures VI, L.P. and 302,770 shares held by 5AM Opportunities II, L.P. Explanatory footnotes state Schwab is a managing member of the general partner entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.
Camp4 Therapeutics insider acquisition: Multiple 5AM-affiliated entities and Kush Parmar reported purchases and beneficial holdings of Camp4 Therapeutics (CAMP) common stock. On 09/11/2025 a purchase transaction (code P) was reported for 2,941,176 shares at $1.53 per share. The filing lists beneficial holdings following the transaction: 2,941,176 shares held by 5AM Ventures VII, L.P., 2,625,145 shares by 5AM Ventures VI, L.P., and 302,770 shares by 5AM Opportunities II, L.P. The reporting parties disclose indirect ownership through related general partner entities and state shared voting and investment power; the statements include disclaimers limiting beneficial ownership to pecuniary interest.
Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.
Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.
The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.